Novavax confirms its COVID-19 vaccine works the same across different batches

NCT ID NCT05463068

Vaccine Sponsor: Novavax Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether three different manufacturing batches (lots) of Novavax's COVID-19 vaccine produce the same immune response and safety in adults. About 900 healthy adults aged 18 to 49 who had already been vaccinated received one of the three lots. The results help ensure that every batch of the vaccine is equally effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

911 people

The number who actually took part.

Started

Jul 2022

Finished

Sep 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be included in this study, each individual must satisfy all of the following criteria: 1. Adults 18 to 49 years of age, inclusive, at screening 2. Willing and able to give informed consent prior to study enrollment and to comply with study procedures. 3. Participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea at least 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (EOS) visit OR agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through the EOS visit. 4. Is medically stable, as determined by the investigator (based on review of health status, vital signs \[to include body temperature\], medical history, and targeted physical examination \[to include body weight\]). Vital signs must be within medically acceptable ranges prior to the study vaccination 5. Agree to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study. Note: For participants who become hospitalized with coronavirus disease 2019 (COVID-19), participation in investigational treatment studies is permitted. 6. Documented receipt of either 2 or 3 doses of the investigational Novavax vaccine with Matrix-M adjuvant (NVX- CoV2373); OR documented receipt of a full course of an FDA-authorized/approved COVID-19 vaccine; OR documented receipt of a full course of heterologous COVID-19 vaccines mentioned above. The most recent dose must have been administered at least 6 months prior to study vaccination. Exclusion Criteria: Participants meeting any of the following criteria will be excluded from the study. 1. History of laboratory-confirmed (by polymerase chain reaction \[PCR\] or rapid antigen test)COVID-19 infection ≤ 4 months prior to randomization. 2. Current participation in research involving receipt of an investigational product (drug/biologic/device). 3. Any known allergies or history of anaphylaxis to the active substance or any of the other ingredients contained in the investigational product. 4. Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) or therapy that causes clinically significant immunosuppression. 5. Received any vaccine ≤ 90 days prior to study vaccination, except for influenza vaccine which may be received 4 days prior to study vaccine, or rabies vaccine which may be received at any time if medically indicated. 6. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated. 7. Active cancer (malignancy) on chemotherapy that is judged to cause significant immunocompromise within 1 year prior to first study vaccination (with the exception of malignancy cured via excision, at the discretion of the investigator). 8. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the EOS visit. 9. Suspected or known history of alcohol abuse or drug addiction within 3 months prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance. 10. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the trial vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting). 11. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization \[CRO\], and study site personnel involved in the conduct or planning of the study). 12. Participants with a history of myocarditis or pericarditis.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS-CoV-2 infection

Contacts and locations

Locations

Accel Clinical Research

DeLand, Florida, 32720, United States
Benchmark Research

Sacramento, California, 95864, United States
Benchmark Research

Austin, Texas, 78705, United States
Benchmark Research

Houston, Texas, 76135, United States
CRA Headlands

Stockbridge, Georgia, 30281, United States
CTI Clinical Research Center

Cincinnati, Ohio, 45212, United States
Cen/Excel ACMR

Atlanta, Georgia, 30331, United States
Jacksonville Center for Clinical Research

Jacksonville, Florida, 32216, United States
Long Beach Clinical Trial Services Inc.

Long Beach, California, 90806, United States
Lynn Health Science Institute

Oklahoma City, Oklahoma, 73112, United States
MedPharmics

Gulfport, Mississippi, 39503, United States
Meridian Clinical Research

Savannah, Georgia, 31406, United States
Meridian Clinical Research

Sioux City, Iowa, 51106, United States
Meridian Clinical Research

Baton Rouge, Louisiana, 70809, United States
Meridian Clinical Research

Norfolk, Nebraska, 68701, United States
Meridian Clinical Research

Omaha, Nebraska, 68134, United States
Meridian Clinical Research

Endwell, New York, 13760, United States
Multi-Specialty Research Associates, Inc.

Lake City, Florida, 32055, United States
OnSite Clinical Solutions, LLC

Charlotte, North Carolina, 28208, United States
Research Centers of America

Hollywood, Florida, 33024, United States
Research Your Health

Plano, Texas, 75093, United States
Rochester Clinical Research

Rochester, New York, 14609, United States
Sundance Clinical Research

St Louis, Missouri, 63141, United States
Tekton Research

Yukon, Oklahoma, 73099, United States
Tekton Research

Austin, Texas, 78747, United States
Tekton Research

San Antonio, Texas, 78229, United States
Velocity Clinical Research

Boise, Idaho, 83642, United States
Velocity Clinical Research

Cleveland, Ohio, 44122, United States
Velocity Clinical Research

Grants Pass, Oregon, 97527, United States
Velocity Clinical Research

East Greenwich, Rhode Island, 02818, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.